HUMIRA® for HCPs - Please see Important Safety Information, including BOXED WARNING on Serious Infections and Malignancy.
SkyRizi™ for HCPs

For Healthcare Professionals

The NEW IL-23 inhibitor from AbbVie indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy1

Nothing less than the opportunity for durable skin clearance1; for your patients, that’s everything

When living with moderate to severe Plaque Psoriasis, SKYRIZI (risankizumab-rzaa) is an option.
Woman jumping into lake

Blue shieldDurable.


Most patients achieved PASI 90 at Week 16 and maintained it at Week 521,2

Blue chartRapid.


Co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16, including improvement 4 weeks after 1st dose1,3

Blue patientClear.


The majority of patients achieved PASI 100 at Week 521,2

Blue calendar dosing chart4 doses per year.


3-month dosing after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1

Nothing less than a commitment to working toward 100% commercial patient access


PASI 90=≥90% improvement in Psoriasis Area and Severity Index;

PASI 100=100% improvement in Psoriasis Area and Severity Index;

sPGA 0/1=static Physician's Global Assessment rating of clear or almost clear.

At week 161: 75% of Skyrizi patients (n=294) achieved pasi 90 in the UltIMMa-2 study vs 2% placebo (n=98) patients

84% of SKYRIZI patients achieved sPGA 0/1 vs 5% placebo patients


UltlMMa-1 results at Week 16
PASI 90: SKYRIZI 75% (n=304), placebo 5% (n=102)
sPGA 0/1: SKYRIZI 88% (n=304), placebo 8% (n=102)

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

P<0.001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2


At Week 16, see results of patients achieveing  PASI 90 in the UltIMMa studies.
Blue chart

At week 521,2: 81% of Skyrizi patients (n=294) achieved pasi 90 in the UltIMMa-2 study; placebo did not continue beyond Week 16


UltlMMa-1 results at Week 52
PASI 90: SKYRIZI 82% (n=304), placebo n/a

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

P<0.001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control over 52 weeks in adult patients with moderate to severe plaque psoriasis.1,2


4 doses per year1


3-month dosing after 2 initiation
doses at Weeks 0 and 4 (150 mg/dose)1

Woman in blue swimsuit
Patient with Skyrizi Complete

Nothing less than a
commitment to working toward
100% commercial patient access


With Skyrizi Complete eligible patients may be able to access their SKYRIZI at no charge until their insurance plan covers SKYRIZI

Eligible patients may be able to access their SKYRIZI at no charge until their insurance plan covers SKYRIZI

Blue shieldDurable.


Most patients achieved PASI 90 at Week 16 and maintained it at Week 521,2

Blue chartRapid.


Co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16, including improvement 4 weeks after 1st dose1,3

Blue patientClear.


The majority of patients achieved PASI 100 at Week 521,2

Blue calendar dosing chart4 doses per year.


3-month dosing after 2 initiation doses at Weeks 0 and 41

Nothing less than a commitment to working toward 100% commercial patient access


IMPORTANT SAFETY INFORMATION AND INDICATION1
Indication

SKYRIZI™ (risankizumab-rzaa) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. 

US-RISN-190098

REFERENCES

  1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
  2. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.
  3. Lebwohl M, Bachelez H, Valdecantos WC, Wu T, Gordon K. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis: an integrated analysis of UltIMMa-1 and UltIMMa-2. Poster presented at: the American Academy of Dermatology Annual Meeting; March 1-5, 2019; Washington, DC.
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION1
Infection SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION1
Indication

SKYRIZI™ (risankizumab-rzaa) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. 

US-RISN-190098